OncoMatch/Clinical Trials/NCT06861244
Embryonal Tumor With Multilayered Rosettes
Is NCT06861244 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Chemotherapy Drug, Cancer - Physician's Choice and Temozolomide for embryonal tumor with multilayered rosettes.
Treatment: Chemotherapy Drug, Cancer - Physician's Choice · Temozolomide — This is an open-label, comprehensive, iterative investigation of evaluating the use of induction chemotherapy, high-dose chemotherapy, and focal radiation therapy in children with newly diagnosed Embryonal Tumor With Multilayered Rosettes (ETMR).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Prior therapy
Cannot have received: radiation therapy
Participants must not have received prior radiation for treatment of tumor.
Cannot have received: tumor-directed therapy (other than surgical resection)
Exception: Cohort 1 only
Cohort 1 participants must not have received any prior tumor-directed therapy other than surgical resection.
Cannot have received: tumor directed investigational agents
Participants who are receiving any other tumor directed investigational agents.
Lab requirements
Blood counts
Peripheral absolute neutrophil count (ANC) > 75,000/mm3; Platelet count > 75,000/mm3 (transfusion independent, defined as not receiving platelet transfusions for at least 72 hours prior to enrollment)
Kidney function
Serum creatinine < 1.5 x ULN based on age and gender
Liver function
Total bilirubin < 1.5 x ULN for age; in presence of Gilbert's syndrome, total bilirubin < 3 x ULN or direct bilirubin < 1.5 x ULN; ALT < 3 x ULN; AST < 3 x ULN
Organ Function Requirements: Peripheral absolute neutrophil count (ANC) > 75,000/mm3; Platelet count > 75,000/mm3 (transfusion independent, defined as not receiving platelet transfusions for at least 72 hours prior to enrollment). Adequate Renal Function defined as: Serum creatinine < 1.5 x upper limit normal (ULN) based on age and gender. Adequate Liver Function defined as: Total bilirubin < 1.5 x upper limit of normal (ULN) for age; in presence of Gilbert's syndrome, total bilirubin < 3 x ULN or direct bilirubin < 1.5 x ULN, ALT < 3 x ULN, AST < 3 x ULN.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Alabama at Birmingham · Birmingham, Alabama
- University of California, San Francisco · San Francisco, California
- Riley Hospital for Children at Indiana University Health · Indianapolis, Indiana
- Johns Hopkins University · Baltimore, Maryland
- Washington University in St. Louis · St Louis, Missouri
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06861244 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radiation therapy, tumor-directed therapy (other than surgical resection), tumor directed investigational agents disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify